Showing posts with label against. Show all posts
Showing posts with label against. Show all posts

Saturday, September 14, 2013

0 Against all odds: anti-IgE for intrinsic asthma?




Thorax doi:10.1136/thoraxjnl-2013-203738




  • Chest clinic



  • Opinion



Against all odds: anti-IgE for intrinsic asthma?


Open Access








  1. Johann Christian Virchow1


+Author Affiliations




  1. 1Department of Pneumology and Critical Care Medicine, University of Rostock, Rostock, Germany




  2. 2Pulmonary Department, Mainz University Hospital, Mainz, Germany





  1. Correspondence toDr Marek Lommatzsch, Abteilung für Pneumologie und Internistische Intensivmedizin, Zentrum für Innere Medizin, Universität Rostock, Ernst-Heydemann-Str. 6, Rostock 18057, Germany;marek.lommatzsch@med.uni-rostock.de




  • Received 14 April 2013


  • Revised 19 April 2013


  • Accepted 26 April 2013


  • Published Online First 24 May 2013




Abstract


For many years, pathogenetic concepts and the results of clinical trials supported the view that anti-IgE treatment is specifically effective in allergic asthma. However, there is now growing clinical and mechanistic evidence suggesting that treatment with the anti-IgE antibody omalizumab can be effective in patients with intrinsic asthma. Therefore, large and well-controlled clinical trials with anti-IgE are urgently warranted in patients with intrinsic asthma. In addition, there is a need to find new biomarkers which can identify patients with asthma who respond to anti-IgE treatment.

This Article











Friday, September 13, 2013

0 IL-17A and Th17 Cells in Lung Inflammation: An Update on the Role of Th17 Cell Differentiation and IL-17R Signaling in Host Defense against Infection




Clinical and Developmental Immunology Volume 2013 (2013), Article ID 267971, 12 pages http://dx.doi.org/10.1155/2013/267971

Review Article

IL-17A and Th17 Cells in Lung Inflammation: An Update on the Role of Th17 Cell Differentiation and IL-17R Signaling in Host Defense against Infection



Center for Comparative Respiratory Biology and Medicine, University of California, Davis, CA 95616, USA

Received 16 March 2013; Accepted 27 June 2013

Academic Editor: Samuel Huber


Copyright © 2013 Hsing-Chuan Tsai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Abstract


The significance of Th17 cells and interleukin- (IL-)17A signaling in host defense and disease development has been demonstrated in various infection and autoimmune models. Numerous studies have indicated that Th17 cells and its signature cytokine IL-17A are critical to the airway’s immune response against various bacteria and fungal infection. Cytokines such as IL-23, which are involved in Th17 differentiation, play a critical role in controlling Klebsiella pneumonia (K. pneumonia) infection. IL-17A acts on nonimmune cells in infected tissues to strengthen innate immunity by inducing the expression of antimicrobial proteins, cytokines, and chemokines. Mice deficient in IL-17 receptor (IL-17R) expression are susceptible to infection by various pathogens. In this review, we summarize the recent advances in unraveling the mechanism behind Th17 cell differentiation, IL-17A/IL-17R signaling, and also the importance of IL-17A in pulmonary infection.